# A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

> **NCT04184622** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 2539 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04184622
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-04
- **Primary completion:** 2022-04-01
- **Final completion:** 2024-07-06
- **Target enrollment:** 2539 (ACTUAL)
- **Last updated:** 2025-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04184622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04184622, "A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04184622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*